Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine

Stock Information for Aspen Group Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aspen Group Inc.

AC Immune to Present at the Jefferies 2025 London Healthcare Conference
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.